Raymond James & Associates Eye Point Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 10,739 shares of EYPT stock, worth $145,728. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,739Holding current value
$145,728% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding EYPT
# of Institutions
160Shares Held
67.1MCall Options Held
214KPut Options Held
994K-
Cormorant Asset Management, LP Boston, MA8.33MShares$113 Million7.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$92.3 Million2.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.8MShares$92.3 Million0.11% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.6MShares$62.4 Million0.09% of portfolio
-
Franklin Resources Inc San Mateo, CA4.3MShares$58.4 Million0.01% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $462M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...